Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Adaptive Biotechnologies Corporation provides life science equipment. The Company offers testing instruments for diagnose, treat, and monitor disease. Adaptive Biotechnologies serves customers in the United States.
Website: adaptivebiotech.com



Growth: Good revenue growth rate 53.2%, there is acceleration compared to average historical growth rates 17.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +47.5%

Profitability: LTM EBITDA margin is negative, -14.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 718.8% higher than minimum and 6.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.2x by EV / Sales multiple , the company can be 77.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $27.7 mln (-1.056% of cap.)

Key Financials (Download financials)

Ticker: ADPT
Share price, USD:  (0.0%)19.12
year average price 12.43  


year start price 7.84 2025-02-08

min close price 6.67 2025-03-10

max close price 20.46 2025-11-24

current price 19.12 2026-02-07
Common stocks: 152 432 307

Dividend Yield:  0.0%
EV / Sales: 10.0x
Margin (EBITDA LTM / Revenue): -14.4%
Fundamental value created in LTM:
Market Cap ($m): 2 915
Net Debt ($m): -142
EV (Enterprise Value): 2 773
Price to Book: 14.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-06seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

2026-02-05zacks.com

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

2026-02-05zacks.com

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

2026-01-22globenewswire.com

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

2026-01-12seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-09globenewswire.com

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

2025-11-05zacks.com

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

2025-09-01zacks.com

Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice

2025-08-25zacks.com

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

2025-08-13zacks.com

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-31 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
filingDate 2026-02-05 2025-03-03 2024-02-29 2023-02-14 2022-02-15 2021-02-24
acceptedDate 2026-02-05 16:15:24 2025-11-05 16:31:01 2025-08-05 16:31:13 2025-03-03 16:36:18 2024-11-07 16:30:29 2024-08-01 16:30:28 2024-05-07 16:30:43 2024-02-29 16:15:41 2023-11-09 16:30:32 2023-08-02 16:31:38 2023-05-03 16:32:35 2023-02-14 16:32:14 2022-11-03 16:31:19 2022-02-15 16:31:38 2021-02-24 16:31:08
fiscalYear 2025 2024 2023 2022 2021 2020
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 277M 94M 59M 179M 46M 43M 42M 170M 38M 49M 38M 185M 48M 154M 98M
costOfRevenue 71M 18M 18M 72M 17M 22M 18M 76M 19M 18M 19M 58M 15M 49M 23M
grossProfit 206M 76M 41M 107M 30M 21M 24M 95M 19M 31M 19M 127M 33M 105M 76M
researchAndDevelopmentExpenses 94M 24M 24M 103M 24M 23M 30M 122M 29M 32M 33M 142M 36M 142M 116M
generalAndAdministrativeExpenses 73M 18M 18M 73M 17M 18M 20M 84M 20M 22M 21M 89M 21M 75M 50M
sellingAndMarketingExpenses 95M 23M 24M 85M 21M 20M 22M 89M 20M 24M 22M 96M 22M 95M 61M
sellingGeneralAndAdministrativeExpenses 167M 41M 41M 158M 38M 38M 42M 173M 41M 46M 43M 184M 42M 170M 111M
otherExpenses 2M 428 000 423 000 9M 428 000 8M 423 000 27M 428 000 423 000 419 000 2M 428 000 2M 2M
operatingExpenses 263M 66M 66M 269M 62M 61M 73M 322M 70M 79M 76M 328M 78M 314M 229M
costAndExpenses 334M 84M 84M 342M 79M 83M 91M 397M 89M 97M 95M 385M 93M 363M 251M
netInterestIncome 0 3M 2M -182 000 2M 7M
interestIncome 0 2M 2M 15M 3M 4M 4M 16M 4M 4M 3M 4M 765 000 2M 7M
interestExpense -12M 3M 3M 12M 3M 3M 3M 14M -4M 4M 4M 4M 653 000 0 0
depreciationAndAmortization 0 4M 5M 19M 5M 5M 5M 22M 6M 6M 8M 21M 6M 14M 8M
ebitda -57M 17M -18M -129M -25M -39M -39M -189M -51M -39M -49M -175M -39M -193M -144M
ebit 0 -148M -212M -196M -207M -153M
nonOperatingIncomeExcludingInterest 0 -15M -16M -4M -2M 0
operatingIncome -57M 10M -25M -163M -33M -39M -49M -227M -51M -48M -57M -200M -45M -209M -153M
totalOtherIncomeExpensesNet -2M -744 000 -557 000 3M 561 000 1M 1M 2M 656 000 8000 -507 000 -182 000 112 000 2M 7M
incomeBeforeTax -59M 10M -26M -160M -32M -46M -48M -225M -50M -48M -58M -200M -45M -207M -146M
incomeTaxExpense 0 0 0 0 0 -26 000 4M 0 -6M 4M 4M 0 -150 000 0 0
netIncomeFromContinuingOperations 0 -160M -225M -200M -207M -146M
netIncomeFromDiscontinuedOperations 0 0 0 0 0 0
otherAdjustmentsToNetIncome -59M 0 0 0 0 0
netIncome -59M 10M -26M -159M -32M -46M -48M -225M -50M -48M -62M -200M -45M -207M -146M
netIncomeDeductions 0 0 0 0 0 0
bottomLineNetIncome -59M -159M -225M -200M -207M -146M
eps -0.39 0.06 -0.17 -1.08 -0.22 -0.31 -0.33 -1.56 -0.35 -0.33 -0.43 -1 -0.32 -1.46 -1.06
epsDiluted -0.39 -1.08 -1.56 -1 -1.46 -1.06
weightedAverageShsOut 152M 152M 152M 147M 148M 147M 146M 144M 145M 144M 144M 143M 143M 140M 131M
weightedAverageShsOutDil 152M 163M 152M 147M 148M 147M 146M 144M 145M 144M 144M 143M 143M 140M 131M
fillingDate 2025-11-05 2025-08-05 2024-11-07 2024-08-01 2024-05-07 2023-11-09 2023-08-02 2023-05-03 2022-11-03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
grossProfitRatio 0.807 0.694 0.641 0.488 0.569 0.49 0.634 0.504 0.688
ebitdaratio 0.18 -0.308 -0.529 -0.797 -0.939 -1.344 -0.788 -1.295 -0.821
operatingIncomeRatio 0.109 -0.425 -0.703 -0.913 -1.165 -1.344 -0.977 -1.519 -0.95
incomeBeforeTaxRatio 0.102 -0.435 -0.691 -1.071 -1.135 -1.327 -0.977 -1.533 -0.948
netIncomeRatio 0.102 -0.435 -0.691 -1.07 -1.135 -1.327 -0.977 -1.64 -0.944
epsdiluted 0.06 -0.17 -0.22 -0.31 -0.33 -0.35 -0.33 -0.43 -0.32
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-05 2024-11-07 2024-08-01 2024-05-07 2023-11-09 2023-08-02 2023-05-03 2022-11-03
acceptedDate 2025-11-05 16:31:01 2025-08-05 16:31:13 2025-03-03 16:36:18 2024-11-07 16:30:29 2024-08-01 16:30:28 2024-05-07 16:30:43 2024-02-29 16:15:41 2023-11-09 16:30:32 2023-08-02 16:31:38 2023-05-03 16:32:35 2023-02-14 16:32:14 2022-11-03 16:31:19 2022-02-15 16:31:38 2021-02-24 16:31:08
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 55M 43M 48M 38M 60M 71M 65M 89M 109M 95M 90M 218M 139M 123M
shortTermInvestments 158M 155M 174M 205M 232M 238M 281M 282M 308M 346M 408M 291M 214M 565M
cashAndShortTermInvestments 213M 198M 222M 243M 292M 309M 346M 371M 417M 441M 498M 508M 353M 688M
netReceivables 46M 44M 42M 41M 36M 42M 38M 31M 32M 31M 40M 27M 17M 10M
inventory 10M 8M 8M 12M 13M 13M 14M 19M 19M 20M 14M 17M 19M 14M
otherCurrentAssets 12M 11M 11M 12M 20M 10M 11M 13M 9M 10M 9M 12M 0 0
totalCurrentAssets 281M 262M 284M 308M 352M 374M 410M 435M 477M 501M 562M 564M 403M 727M
propertyPlantEquipmentNet 79M 84M 94M 98M 104M 116M 120M 152M 156M 160M 164M 169M 173M 139M
goodwill 119M 119M 119M 119M 119M 119M 119M 119M 119M 119M 119M 119M 119M 119M
intangibleAssets 2M 3M 3M 4M 4M 5M 5M 6M 6M 6M 7M 7M 9M 10M
goodwillAndIntangibleAssets 121M 122M 122M 123M 123M 124M 124M 125M 125M 125M 126M 126M 127M 129M
longTermInvestments 7M 24M 34M 24M 3M 3M 0 3M 0 0 0 20M 217M 119M
taxAssets 0 0 0 0 -1 -3M 0 -3M 0 0 0 0 0 0
otherNonCurrentAssets 2M 5M 5M 6M 3M 6M 7M 6M 6M 4M 4M 5M 3M 3M
totalNonCurrentAssets 209M 235M 256M 250M 233M 246M 251M 282M 288M 290M 294M 320M 521M 390M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 491M 497M 539M 559M 585M 620M 661M 718M 765M 791M 857M 884M 923M 1 116M
accountPayables 10M 7M 7M 7M 10M 12M 8M 4M 9M 6M 8M 4M 3M 3M
shortTermDebt 12M 10M 0 10M 20M 10M 0 9M 9M 9M 0 9M 0 0
taxPayables 0 0 176 000 0 0 0 59 000 0 0 0 194 000 0 391 000 2M
deferredRevenue 41M 55M 56M 52M 52M 47M 49M 55M 58M 60M 64M 68M 80M 73M
otherCurrentLiabilities 20M 20M 17M 18M 6M 14M 14M 24M 19M 14M 16M 23M 16M 12M
totalCurrentLiabilities 83M 92M 98M 88M 88M 83M 88M 93M 95M 90M 110M 104M 114M 105M
longTermDebt 202M 74M 0 82M 216M 87M 0 92M 94M 96M 0 101M 0 0
deferredRevenueNonCurrent 1M 20M 27M 0 39M 44M 45M 44M 51M 54M 59M 67M 99M 164M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 84M 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 20 000 131M 132M 166M 20 000 132M 131M 127M 128M 127M 125M 212M 0 0
totalNonCurrentLiabilities 203M 225M 239M 247M 255M 263M 265M 263M 273M 277M 283M 292M 205M 268M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 72M 84M 89M 92M 94M 96M 99M 101M 104M 106M 108M 109M 112M 108M
totalLiabilities 286M 317M 337M 335M 343M 346M 353M 356M 369M 368M 393M 396M 319M 373M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 15 000 15 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000 14 000
retainedEarnings -1 350M -1 359M -1 304M -1 270M -1 238M -1 192M -1 144M -1 075M -1 025M -977M -919M -879M -719M -512M
accumulatedOtherComprehensiveIncomeLoss 211 000 73 000 166 000 0 -182 000 -106 000 215 000 -250 000 -893 000 -2M -4M -6M -1M 893 000
othertotalStockholdersEquity 1 554M 1 539M 1 494M 1 480M 1 467M 1 437M 1 422M 1 403M 1 373M
totalStockholdersEquity 204M 180M 203M 224M 242M 275M 308M 362M 396M 424M 464M 488M 604M 743M
totalEquity 204M 180M 202M 224M 241M 275M 308M 362M 396M 424M 464M 488M 604M 743M
totalLiabilitiesAndStockholdersEquity 491M 497M 559M 585M 620M 718M 765M 791M 884M
minorityInterest -182 000 -181 000 -224 000 -199 000 -173 000 -147 000 -121 000 -95 000 -69 000 -68 000 -67 000 0 110 000 0
totalLiabilitiesAndTotalEquity 491M 497M 539M 559M 585M 620M 661M 718M 765M 791M 857M 884M 923M 1 116M
totalInvestments 164M 179M 208M 229M 235M 238M 281M 282M 308M 346M 408M 310M 431M 683M
totalDebt 214M 84M 89M 92M 226M 96M 99M 101M 104M 106M 108M 109M 112M 108M
netDebt 159M 41M 41M 54M 166M 25M 34M 13M -6M 11M 18M -109M -27M -16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-03 2024-02-29 2023-02-14 2022-02-15 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 42M 38M 40M 17M 10M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 13M 15M
totalPayables 7M 8M 8M 4M 5M
otherPayables 176 000 59 000 194 000 391 000 2M
accruedExpenses 8M 9M 12M 9M 11M
capitalLeaseObligationsCurrent 10M 9M 9M 5M 4M
capitalLeaseObligationsNonCurrent 79M 89M 99M 107M 104M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 506M 1 453M 1 387M 1 324M 1 254M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT ADPT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-05 2024-11-07 2024-08-01 2024-05-07 2023-11-09 2023-08-02 2023-05-03 2022-11-03
acceptedDate 2025-11-05 16:31:01 2025-08-05 16:31:13 2025-03-03 16:36:18 2024-11-07 16:30:29 2024-08-01 16:30:28 2024-05-07 16:30:43 2024-02-29 16:15:41 2023-11-09 16:30:32 2023-08-02 16:31:38 2023-05-03 16:32:35 2023-02-14 16:32:14 2022-11-03 16:31:19 2022-02-15 16:31:38 2021-02-24 16:31:08
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 10M -26M -160M -32M -46M -48M -225M -50M -48M -58M -200M -45M -207M -146M
depreciationAndAmortization 4M 5M 19M 5M 5M 5M 22M 6M 6M 5M 28M 5M 21M 8M
deferredIncomeTax 0 0 0 0 0 0 0 -3M -2M 0 0 0 0 773 000
stockBasedCompensation 0 13M 54M 14M 13M 14M 0 15M 17M 15M 0 14M 0 25M
changeInWorkingCapital -34M -5M -17M 7M 3M -10M -46M -19M 449 000 -24M -72M -19M -57M -41M
accountsReceivables -536 000 -702 000 -4M -5M 6M -4M 2M 334 000 -621 000 9M -23M -3M -7M 3M
inventory -1M 95 000 2M 1M -818 000 1M -3M -273 000 65 000 -7M 817 000 72 000 -5M -5M
accountsPayables 6M 3M 671 000 -59 000 407 000 -4M -5M -7M 9M -16M 7M 0 4M 5M
otherWorkingCapital -38M -8M -16M 12M -3M -5M -40M -12M -8M -11M -57M -17M -48M -44M
otherNonCashItems 13M 607 000 9M -21M 25M 2M 93M 4M 3M 3M 60M 3M 50M 3M
netCashProvidedByOperatingActivities -7M -12M -95M -27M -17M -38M -156M -47M -24M -59M -184M -42M -193M -150M
investmentsInPropertyPlantAndEquipment -409 000 -655 000 -4M -344 000 -2M -2M -11M -3M -4M -3M -16M -5M -62M -19M
acquisitionsNet 0 0 0 0 0 0 0 -29M 0 0 0 0 0 98M
purchasesOfInvestments -33M -51M -244M -63M -83M -53M -430M -119M -99M -89M -279M -29M -317M -695M
salesMaturitiesOfInvestments 51M 55M 326M 69M 90M 100M 570M 148M 140M 155M 298M 92M 560M 597M
otherInvestingActivites 0 0 0 8M 46M 29M 0 0 0
netCashUsedForInvestingActivites 17M 3M 5M 6M 45M 26M 37M 63M 58M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 2M 2M -74 000 30 000 44 000 17 000 0 672 000 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 40 000 30 000 44 000 17 000 0 0 126M
netCashUsedProvidedByFinancingActivities 2M 2M 40 000 30 000 44 000 17 000 1M 672 000 126M
effectOfForexChangesOnCash 31 000 0 0 0 0 0 -534 000 -9M -40M 0 -259 999 0 0 0
netChangeInCash 12M -7M -17M -19M -11M 6M -25M -21M 15M 4M -49M 141M 16M 27M
cashAtEndOfPeriod 55M 46M 51M 41M 60M 74M 65M 92M 112M 97M 90M 220M 139M 126M
cashAtBeginningOfPeriod 43M 53M 68M 60M 71M 68M 90M 112M 97M 92M 139M 79M 123M 99M
operatingCashFlow -7M -12M -95M -27M -17M -38M -156M -47M -24M -59M -184M -42M -193M -150M
capitalExpenditure -409 000 -655 000 -4M -344 000 -2M -2M -11M -3M -4M -3M -16M -5M -62M -19M
freeCashFlow -8M -13M -99M -27M -19M -40M -167M -49M -27M -62M -200M -48M -254M -168M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-03 2024-02-29 2023-02-14 2022-02-15 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 -98M
netCashProvidedByInvestingActivities 78M 130M 3M 181M -117M
netDebtIssuance 0 0 124M 0 0
longTermNetDebtIssuance 0 0 124M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 241 000 2M 8M 27M 272M
netCommonStockIssuance 241 000 2M 8M 27M 272M
commonStockIssuance 241 000 2M 8M 27M 272M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 429 000 21M
netCashProvidedByFinancingActivities 241 000 2M 132M 27M 294M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q4
2026-02-05 ET (fiscal 2025 q4)
2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-11 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-14 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-05 21:15 ET
Adaptive Biotechnologies reported for 2025 q4
SEC form 8
2026-02-05 21:15 ET
Adaptive Biotechnologies published news for 2025 q4
SEC form 10
2025-11-05 16:31 ET
Adaptive Biotechnologies reported for 2025 q3
SEC form 8
2025-11-05 16:15 ET
Adaptive Biotechnologies published news for 2025 q3
SEC form 8
2025-11-05 16:15 ET
Adaptive Biotechnologies published news for 2025 q3
SEC form 10
2025-08-05 20:31 ET
Adaptive Biotechnologies reported for 2025 q2
SEC form 8
2025-08-05 20:15 ET
Adaptive Biotechnologies published news for 2025 q2
SEC form 8
2025-08-05 20:15 ET
Adaptive Biotechnologies published news for 2025 q2
SEC form 10
2025-05-01 20:30 ET
Adaptive Biotechnologies reported for 2025 q1
SEC form 8
2025-05-01 20:15 ET
Adaptive Biotechnologies published news for 2025 q1
SEC form 8
2025-05-01 20:15 ET
Adaptive Biotechnologies published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Adaptive Biotechnologies published news for 2025 q1
SEC form 10
2025-03-03 21:36 ET
Adaptive Biotechnologies published news for 2024 q4
SEC form 10
2025-03-03 00:00 ET
Adaptive Biotechnologies published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Adaptive Biotechnologies reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Adaptive Biotechnologies published news for 2024 q4
SEC form 10
2024-11-07 16:30 ET
Adaptive Biotechnologies reported for 2024 q3
SEC form 8
2024-11-07 16:15 ET
Adaptive Biotechnologies published news for 2024 q3
SEC form 8
2024-11-07 16:15 ET
Adaptive Biotechnologies published news for 2024 q3
SEC form 10
2024-08-01 16:30 ET
Adaptive Biotechnologies reported for 2024 q2
SEC form 8
2024-08-01 16:15 ET
Adaptive Biotechnologies published news for 2024 q2
SEC form 8
2024-08-01 16:15 ET
Adaptive Biotechnologies published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Adaptive Biotechnologies published news for 2024 q2
SEC form 10
2024-05-07 16:30 ET
Adaptive Biotechnologies reported for 2024 q1
SEC form 8
2024-05-07 16:15 ET
Adaptive Biotechnologies reported for 2024 q1
SEC form 8
2024-05-07 16:15 ET
Adaptive Biotechnologies published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Adaptive Biotechnologies published news for 2024 q1
SEC form 8
2024-04-05 00:00 ET
Adaptive Biotechnologies published news for 2024 q1
SEC form 8
2024-04-05 00:00 ET
Adaptive Biotechnologies published news for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Adaptive Biotechnologies published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Adaptive Biotechnologies published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Adaptive Biotechnologies reported for 2023 q4
SEC form 10
2023-11-09 16:30 ET
Adaptive Biotechnologies reported for 2023 q3
SEC form 8
2023-11-09 16:15 ET
Adaptive Biotechnologies published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Adaptive Biotechnologies published news for 2023 q3
SEC form 10
2023-08-02 16:31 ET
Adaptive Biotechnologies reported for 2023 q2
SEC form 6
2023-08-02 16:17 ET
Adaptive Biotechnologies published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Adaptive Biotechnologies published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Adaptive Biotechnologies published news for 2023 q2
SEC form 6
2023-07-03 15:14 ET
Adaptive Biotechnologies published news for 2023 q2
SEC form 6
2023-06-13 16:30 ET
Adaptive Biotechnologies published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Adaptive Biotechnologies published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Adaptive Biotechnologies published news for 2023 q1
SEC form 10
2023-02-14 00:00 ET
Adaptive Biotechnologies reported for 2022 q4
SEC form 8
2023-02-14 00:00 ET
Adaptive Biotechnologies reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
Adaptive Biotechnologies reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Adaptive Biotechnologies reported for 2022 q3
SEC form 8
2022-08-03 00:00 ET
Adaptive Biotechnologies reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Adaptive Biotechnologies reported for 2022 q2
SEC form 8
2022-05-04 00:00 ET
Adaptive Biotechnologies reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Adaptive Biotechnologies reported for 2022 q1
SEC form 8
2022-02-15 00:00 ET
Adaptive Biotechnologies published news for 2021 q4
SEC form 10
2022-02-15 00:00 ET
Adaptive Biotechnologies published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Adaptive Biotechnologies published news for 2021 q4
SEC form 8
2021-11-03 00:00 ET
Adaptive Biotechnologies published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Adaptive Biotechnologies published news for 2021 q3
SEC form 8
2021-08-04 00:00 ET
Adaptive Biotechnologies published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Adaptive Biotechnologies published news for 2021 q2
SEC form 8
2021-05-05 00:00 ET
Adaptive Biotechnologies published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Adaptive Biotechnologies published news for 2021 q1